<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, Yan</style></author><author><style face="normal" font="default" size="100%">Xiao, Juxiang</style></author><author><style face="normal" font="default" size="100%">Fang, Wentao</style></author><author><style face="normal" font="default" size="100%">Lu, Ping</style></author><author><style face="normal" font="default" size="100%">Fan, Qingxia</style></author><author><style face="normal" font="default" size="100%">Shu, Yongqian</style></author><author><style face="normal" font="default" size="100%">Feng, Jifeng</style></author><author><style face="normal" font="default" size="100%">Zhang, Shu</style></author><author><style face="normal" font="default" size="100%">Ba, Yi</style></author><author><style face="normal" font="default" size="100%">Zhao, Yang</style></author><author><style face="normal" font="default" size="100%">Liu, Ying</style></author><author><style face="normal" font="default" size="100%">Bai, Chunmei</style></author><author><style face="normal" font="default" size="100%">Bai, Yuxian</style></author><author><style face="normal" font="default" size="100%">Tang, Yong</style></author><author><style face="normal" font="default" size="100%">He, Jie</style></author><author><style face="normal" font="default" size="100%">Huang, Jing</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Biology and Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">562-568</style></pages><doi><style  face="normal" font="default" size="100%">10.20892/j.issn.2095-3941.2020.0187</style></doi><volume><style face="normal" font="default" size="100%">18</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Objective: In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma (ESCC) patients.Methods: A total of 109 patients enrolled in the anlotinib group in a phase 2 trial were included. The tumor response was assessed by computed tomography at week 3, week 6, and then every 6 weeks until progressive disease was observed. The primary endpoint of the study was progression free survival (PFS). The secondary endpoints included overall survival (OS) and objective response rate (ORR).Results: In all patients, the median PFS was 3.02 months [95% confidence interval (CI): 2.63–3.65 months] and the OS was 6.11 months (95% CI: 4.40–7.79 months). The ORR was 7.34% (95% CI: 3.22%–13.95%). A total of 59 (54%) patients were diagnosed with treatment-induced hypertension (Group A), and the remaining patients (n = 50, 46%) were in Group B. Baseline prognostic factors were similar between the 2 groups. Patients in Group A had a longer PFS and OS and higher ORR. When stratifying patients using a previously known history of hypertension, treatment-induced hypertension was a predictor only for patients without previous hypertension, who had longer PFS [hazard ratio (HR): 0.40, 95% CI: 0.24–0.68] and OS (HR: 0.37, 95% CI: 0.21–0.67).Conclusions: We showed, for the first time, a correlation between treatment-induced hypertension and better prognoses in recurrent or metastatic ESCC patients treated with anlotinib, without a previously known history of hypertension. Treatment-induced hypertension may be a simple and low cost predictor for anlotinib antitumor efficacy in these patients, which may also reflect the intended target inhibition.</style></abstract></record></records></xml>